NeuroBo Pharmaceuticals, Inc.
NASDAQ Capital MarketCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Hyung-Heon Kim
- Full Time Employees
- 8
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 200 Berkeley Street Boston MA United States of America 02116
- IPO Date
- Aug 5, 2016
- CIK
- 0001638287
- Website
- neurobopharma.com
- Similar Companies
- Business
- MetaVia Inc. (Nasdaq: MTVA), formerly NeuroBo Pharmaceuticals, Inc., is a clinical-stage biotechnology company that develops novel therapeutics targeting cardiometabolic diseases, including obesity and metabolic dysfunction-associated steatohepatitis (MASH); its lead pipeline candidates include DA-1726, a dual oxyntomodulin analog agonist of glucagon-like peptide-1 receptor (GLP1R) and glucagon receptor (GCGR) for obesity that promotes appetite suppression and energy expenditure, and DA-1241, a G-protein-coupled receptor 119 (GPR119) agonist that enhances gut hormone release to improve liver inflammation, lipid metabolism, glucose control, hepatic steatosis, and fibrosis in MASH. The company previously advanced neurodegenerative and pain-focused assets such as NB-01 for painful diabetic neuropathy, NB-02 for tauopathies including Alzheimer's disease, ANA001 (niclosamide formulation) for COVID-19, and Gemcabene for dyslipidemia and viral indications, though it has out-licensed NB-01 worldwide outside Korea to MThera Pharma in July 2024. Founded in 2014 and headquartered in Cambridge, Massachusetts, MetaVia in-licenses assets primarily from Dong-A ST Co., Ltd., a key strategic partner and shareholder based in South Korea, with operations centered in the United States and development manufacturing in Korea. Recent major developments include a strategic corporate rebranding from NeuroBo Pharmaceuticals to MetaVia effective November 29, 2024, to emphasize its cardiometabolic focus; a June 2024 financing securing up to $70 million ($20 million upfront and $50 million milestone-based) to fund clinical advancement; Phase 2a topline data readout for DA-1241 expected in December 2024; and Phase 1 multiple ascending dose results for DA-1726 anticipated in Q1 2025.
NeuroBo Pharmaceuticals Announces Strategic Realignment Ahead of Important Clinical Milestones with Name Change to MetaVia - Reflecting the Company's Focus on Cardiometabolic Diseases
NeuroBo Pharmaceuticals to Participate in Investor Conferences in November
NeuroBo Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Corporate Update
NeuroBo Pharmaceuticals Completes Last Patient Last Visit in Its Phase 2a Clinical Trial Evaluating DA-1241 for the Treatment of MASH
NeuroBo Pharmaceuticals to Participate in Investor Conferences in October
NeuroBo Pharmaceuticals Announces Positive Top-Line Data From the SAD Part 1 of Its Phase 1 Clinical Trial Evaluating DA-1726 for the Treatment of Obesity
NeuroBo to Participate in the H.C. Wainwright 26th Annual Global Investment Conference
NeuroBo Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides Corporate Update
NeuroBo Pharmaceuticals Completes Enrollment of the SAD Part 1 of Its Phase 1 Clinical Trial Evaluating DA-1726 for the Treatment of Obesity
NeuroBo Pharmaceuticals Announces Joint Research Agreement, Together with Dong-A ST and ImmunoForge to Develop a Long-Acting Once-Monthly Formulation of DA-1726 for the Treatment of Obesity
NeuroBo Pharmaceuticals Announces Exclusive License Agreement with MThera Pharma for NB-01
NeuroBo Pharmaceuticals to Present at the Emerging Growth Conference in July
Huge Insider Buying at a Warren Buffett Pick and 5 Other Stocks
NeuroBo Pharmaceuticals Announces the Closing of up to $70 Million Concurrent Private Placement and Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
NeuroBo Pharmaceuticals Announces up to $70 Million Concurrent Private Placement and Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
NeuroBo Pharmaceuticals' DA-1726 Demonstrated Superiority in Weight Loss, Retention of Lean Body Mass, and Lipid-Lowering Effects Compared to Survodutide, in Pre-Clinical Models
NeuroBo Pharmaceuticals' DA-1241 in Combination with Semaglutide Improves Liver Fibrosis and Demonstrates Additive Hepatoprotective Effects in Pre-Clinical MASH Models Compared to Either Treatment, Alone
NeuroBo Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Corporate Update
NeuroBo to Present Latest Pre-Clinical Data on Cardiometabolic Assets, DA-1241 and DA-1726, Targeting MASH and Obesity, at Scientific Conferences in June
NeuroBo Pharmaceuticals Doses First Patient in Its Phase 1 Clinical Trial Evaluating DA-1726 for the Treatment of Obesity